<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.deals.v2.DealRecordsOutput xmlns:ns2="local"><serviceExecutionTime>271</serviceExecutionTime><Deal id="113686"><Title>Tercica and Ipsen to crosslicense Somatuline Autogel and Increlex</Title><CompanyPrincipal id="17259">Ipsen</CompanyPrincipal><CompanyPartner id="29694">Ipsen Biopharmaceuticals Inc</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="~" max="25.0" min="25.0"></ValuePaid><ValueProjected accuracy="&gt;" max="125.2" min="125.2"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="10.0" min="10.0"></ValuePaid><ValueProjected accuracy="~" max="216.8" min="216.8"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="CA">Canada</Territory><Territory id="US">US</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>1646155</Reference><Type>Upfront Equity</Type><Value accuracy="~"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="77.3" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="~"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="18.6" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Equity</Type><Value accuracy="~"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="77.3" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="~"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="18.6" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q2">25.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q2">20.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="~"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="12.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="~"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="12.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q2">25.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q2">20.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q2">25.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q2">20.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="25.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q2">20.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q2">25.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="25.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="37.6" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Contingent Equity</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="37.6" usdExchangeRate="1.0" usdExchangeRatePeriod="2006 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Contingent Equity</Type><Value accuracy="Payment Unspecified"></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="2535">Growth hormone deficiency</Indication><Indication id="140">Growth disorder</Indication><Indication id="684">Nutritional disorder</Indication></Indications><ActionsPrimary><Action id="1120">Somatostatin receptor agonist</Action><Action id="1637">Insulin-like growth factor 1 receptor agonist</Action><Action id="1919">Insulin sensitizer</Action><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2657">Antihypertensive</Action><Action id="1545">Anticancer</Action><Action id="2660">Vasoprotectant</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="80">Peptide</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="1099">In-licensed product deal</Technology><Technology id="596">Injectable formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><DateStart>2006-07-18T00:00:00Z</DateStart><DateEventMostRecent>2008-10-17T00:00:00Z</DateEventMostRecent><Drugs><Drug id="4431"><DrugNameDisplay>mecasermin (growth failure), Ipsen</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="9313"><DrugNameDisplay>lanreotide</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In July 2006, &lt;ulink linkType="Company" linkID="29694"&gt;Tercica&lt;/ulink&gt; licensed from &lt;ulink linkType="Company" linkID="17259"&gt;Ipsen&lt;/ulink&gt; rights to develop and market &lt;ulink linkType="Drug" linkID="9313"&gt;Somatuline Autogel&lt;/ulink&gt; in the United States and Canada.   Ipsen  acquired worldwide rights to Tercica's &lt;ulink linkType="Drug" linkID="4431"&gt;Increlex&lt;/ulink&gt; (mecasermin), excluding the US, Japan, Canada, Middle East and Taiwan in cross licensing[&lt;ulink linkType="Reference" linkID="678965"&gt;678965&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1646155"&gt;1646155&lt;/ulink&gt;].In August 2007, Tercica acheived FDA approval triggering the payment of a milestone payment to Ipsen [&lt;ulink linkType="Reference" linkID="826234"&gt;826234&lt;/ulink&gt;]. In October 2008, Ipsen acquired Tercica [&lt;ulink linkType="Reference" linkID="953341"&gt;953341&lt;/ulink&gt;].&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;</Summary><TimeLine><Event><Date>2008-10-17T00:00:00Z</Date><Drugs><DrugLink id="9313" nameDisplay="lanreotide"></DrugLink></Drugs><Summary>&lt;para&gt;In October 2008, Ipsen acquired Tercica [&lt;ulink linkType="Reference" linkID="953341"&gt;953341&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>M&amp;amp;A Activity</Type></Event><Event><Date>2006-07-18T00:00:00Z</Date><Drugs><DrugLink id="4431" nameDisplay="mecasermin (growth failure), Ipsen"></DrugLink><DrugLink id="9313" nameDisplay="lanreotide"></DrugLink></Drugs><PaymentsToPartner><Payment><Reference id="678965">678965</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2006 Q2" exchangeRateUS="1">10</USDAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference id="678965">678965</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="5">~</Accuracy><USDAmountMil exchangeRatePeriod="2006 Q2" exchangeRateUS="1">25</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="C3">Phase 3 Clinical</Stage><Summary>&lt;para&gt;- In July 2006, &lt;ulink linkType="Company" linkID="29694"&gt;Tercica&lt;/ulink&gt; licensed from &lt;ulink linkType="Company" linkID="17259"&gt;Ipsen&lt;/ulink&gt; rights to develop and market &lt;ulink linkType="Drug" linkID="9313"&gt;Somatuline Autogel&lt;/ulink&gt; in the United States and Canada. &lt;/para&gt;&lt;para&gt;- Ipsen  acquired worldwide rights to Tercica's &lt;ulink linkType="Drug" linkID="4431"&gt;Increlex&lt;/ulink&gt; (mecasermin), excluding the US, Japan, Canada, Middle East and Taiwan in cross licensing.&lt;/para&gt;&lt;para&gt;- Tercica agreed to pay Ipsen EUR 20 million (approximately $25 million) upfront, EUR 30 million (approximately $37.5 million) upon approval of the drug in the US (for the targeted product label); both payments would be financed by through the issuance of Tercica convertible notes to Ipsen. &lt;/para&gt;&lt;para&gt;- Ipsen also acquired an option (exercisable upon US approval) to purchase in cash a note for a principal amount of $15.0 million convertible into Tercica common stock. &lt;/para&gt;&lt;para&gt;- Tercica also agreed to pay royalties to its partner on a sliding scale from 15% to 25% of net sales, in addition to a supply price of 20% of net sales of the product. &lt;/para&gt;&lt;para&gt;- Ipsen granted its partner the right to pursue development of new indications and improvements to the drug, either jointly or on its own, but retained an a right to opt in to co-fund development at a  later date.&lt;/para&gt;&lt;para&gt;- Tercica would receive EUR 10 million (approximately $12.5 million) upfront, an additional EUR 15 million (approximately $18.6 million) upon EU approval of the drug, and royalty payments (on a sliding scale from 15% to 25% of net sales, in addition to a supply price of 20% of net sales of the product).  &lt;/para&gt;&lt;para&gt;- Tercica granted its partner the right to pursue development of new indications and improvements to Increlex, either jointly or on its own, but retained an a right to opt in to co-fund development at a  later date.&lt;/para&gt;&lt;para&gt;-  Concurrently, Ipsen and Tercica established financing  agreements, although no terms of those agreements were specific to the Increlex license    [&lt;ulink linkType="Reference" linkID="678965"&gt;678965&lt;/ulink&gt;].  [&lt;ulink linkType="Reference" linkID="678965"&gt;678965&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1646155"&gt;1646155&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2007-08-31T00:00:00Z</Date><Drugs><DrugLink id="4431" nameDisplay="mecasermin (growth failure), Ipsen"></DrugLink><DrugLink id="9313" nameDisplay="lanreotide"></DrugLink></Drugs><Summary>&lt;para&gt;In August 2007, the FDA approved the drug. This triggered the   issuance of a convertible bond to Ipsen worth EUR 30 million (approximately $40.4 million). Simultaneously, Ipsen exercised its option to purchase an additional $15 million convertible bond from Tercica [&lt;ulink linkType="Reference" linkID="826234"&gt;826234&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Regulatory Milestone</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="4431" type="Drug"><TargetEntity id="198475" type="siDrug">Mecasermin</TargetEntity></SourceEntity><SourceEntity id="9313" type="Drug"><TargetEntity id="131415" type="siDrug">Lanreotide acetate</TargetEntity></SourceEntity><SourceEntity id="29694" type="Company"><TargetEntity id="4295900085" type="organizationId">Ipsen Biopharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="17259" type="Company"><TargetEntity id="4295868520" type="organizationId">Ipsen SA</TargetEntity></SourceEntity><SourceEntity id="140" type="ciIndication"><TargetEntity id="D006130" type="MeSH"></TargetEntity><TargetEntity id="1100" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2535" type="ciIndication"><TargetEntity id="10056438" type="MEDDRA"></TargetEntity><TargetEntity id="D004393" type="MeSH"></TargetEntity><TargetEntity id="516" type="siCondition"></TargetEntity><TargetEntity id="1820" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="684" type="ciIndication"><TargetEntity id="E63.9" type="ICD10"></TargetEntity><TargetEntity id="10003018" type="MEDDRA"></TargetEntity><TargetEntity id="D009748" type="MeSH"></TargetEntity><TargetEntity id="-21513915" type="omicsDisease"></TargetEntity><TargetEntity id="1266" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1919" type="Action"><TargetEntity id="605" type="Mechanism">Insulin Sensitizers</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="3252" type="Action"><TargetEntity id="3642" type="Mechanism">Anti-IGF-1</TargetEntity><TargetEntity id="1104" type="Mechanism">IGF-1R Inhibitors</TargetEntity><TargetEntity id="2556" type="Mechanism">Anti-CD221 (IGF-1R)</TargetEntity></SourceEntity><SourceEntity id="1120" type="Action"><TargetEntity id="306" type="Mechanism">Somatostatin Agonists</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="121139"><Title>Allergan to market ISTA's Vitrase for ocular disease outside Mexico and Japan</Title><CompanyPrincipal id="24620">ISTA Pharmaceuticals Inc</CompanyPrincipal><CompanyPartner id="14042">Allergan Inc</CompanyPartner><Type>Drug - Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="10.0" min="10.0"></ValuePaid><ValueProjected accuracy="&gt;" max="115.0" min="45.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="6.5" min="6.5"></ValuePaid><ValueProjected accuracy="&gt;" max="10.0" min="10.0"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="EU">EU</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>561148</Reference><Type>Other</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="10.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>561148</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>561148</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>374728</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1999 Q4">50.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1999 Q4">50.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1999 Q4">30.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Loan/Credit</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="12.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1999 Q4">30.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Loan/Credit</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="12.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>374728</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1999 Q4">50.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="10.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Sales Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>374728</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="35.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>374728</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="10.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="35.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>374728</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>374728</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>374728</Reference><Type>Sales Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>374728</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1999 Q4">50.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="239">Ocular disease</Indication></Indications><ActionsPrimary><Action id="2618">Hyaluronic acid receptor antagonist</Action><Action id="1369">Hyaluronidase modulator</Action></ActionsPrimary><ActionsSecondary><Action id="7293">Synergist</Action><Action id="968">Coagulation stimulator</Action></ActionsSecondary><Technologies><Technology id="80">Peptide</Technology><Technology id="72">Enzyme</Technology><Technology id="596">Injectable formulation</Technology><Technology id="620">Ophthalmic formulation</Technology></Technologies><DateStart>2000-03-29T00:00:00Z</DateStart><DateEnd>2007-04-30T00:00:00Z</DateEnd><DateEventMostRecent>2007-03-30T00:00:00Z</DateEventMostRecent><Drugs><Drug id="14690"><DrugNameDisplay>hyaluronidase (ovine)</DrugNameDisplay><PhaseHighestStart id="R">Registered</PhaseHighestStart><PhaseHighestNow id="R">Registered</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In March 2000, &lt;ulink linkType="Company" linkID="24620"&gt;ISTA&lt;/ulink&gt; entered into an agreement with &lt;ulink linkType="Company" linkID="14042"&gt;Allergan&lt;/ulink&gt; for the marketing, sale and distribution of &lt;ulink linkType="Drug" linkID="14690"&gt;Vitrase&lt;/ulink&gt; in the US and all international markets, except Mexico and Japan [&lt;ulink linkType="Reference" linkID="374728"&gt;374728&lt;/ulink&gt;]. In September 2004,  ISTA reacquired all rights to market and sell Vitrase for all uses in the US and other markets worldwide. Allergan retained an option to commercialize Vitrase for the posterior segment of the eye in Europe [&lt;ulink linkType="Reference" linkID="561148"&gt;561148&lt;/ulink&gt;]. On April 30, 2007, ISTA notified Allergan that it will not be pursuing approval in Europe and presumed the agreement was terminated [&lt;ulink linkType="Reference" linkID="2094338"&gt;2094338&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="789607"&gt;789607&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2007-03-30T00:00:00Z</Date><Drugs><DrugLink id="14690" nameDisplay="hyaluronidase (ovine)"></DrugLink></Drugs><Summary>&lt;para&gt;- On April 30, 2007, ISTA notified Allergan that it will not be pursuing approval in Europe and presumed the agreement was terminated [&lt;ulink linkType="Reference" linkID="2094338"&gt;2094338&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="789607"&gt;789607&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event><Event><Date>2000-03-29T00:00:00Z</Date><Drugs><DrugLink id="14690" nameDisplay="hyaluronidase (ovine)"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="374728">374728</Reference><Type>Upfront Equity</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="1999 Q4" exchangeRateUS="1">10</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;- In March 2000, &lt;ulink linkType="Company" linkID="24620"&gt;ISTA&lt;/ulink&gt; entered into an agreement with &lt;ulink linkType="Company" linkID="14042"&gt;Allergan&lt;/ulink&gt; for the marketing, sale and distribution of &lt;ulink linkType="Drug" linkID="14690"&gt;Vitrase&lt;/ulink&gt; in the US and all international markets, except Mexico and Japan, until April 2004.&lt;/para&gt;&lt;para&gt;- Allergan agreed to pay royalty on any sales of Vitrase outside the US and was to split any profits on sales of Vitrase in the US on a 50/50 basis.&lt;/para&gt;&lt;para&gt;- Allergan made an equity investment of $10 million and may pay aggregate future milestone payments of up to $35 million.&lt;/para&gt;&lt;para&gt;- Allergan also entered into a credit agreement with ISTA to provide up to $10 million to be used for Vitrase specific development expenses and aggregate amount of this credit line would increase by $2.5 million upon the filing of a NDA  [&lt;ulink linkType="Reference" linkID="374728"&gt;374728&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2004-09-28T00:00:00Z</Date><Drugs><DrugLink id="14690" nameDisplay="hyaluronidase (ovine)"></DrugLink></Drugs><PaymentsToPartner><Payment><Reference id="561148">561148</Reference><Type>Other</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2004 Q2" exchangeRateUS="1">6.5</USDAmountMil></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;- In September 2004,  ISTA reacquired all rights to market and sell Vitrase for all uses in the US and other markets worldwide.&lt;/para&gt;&lt;para&gt;- Allergan retained an option to commercialize Vitrase for the posterior segment of the eye in Europe.&lt;/para&gt;&lt;para&gt;- ISTA was to pay Allergan $10 million, make royalty payments to Allergan on US sales for use in the posterior segment of the eye and was to file Vitrase for vitreous hemorrhage in the EU.&lt;/para&gt;&lt;para&gt;- Allergan was to have an option to commercialize Vitrase in Europe subsequent to approval. If Allergan did not exercise this option, then the European rights were to revert to ISTA, and Allergan would be paid a royalty on European sales [&lt;ulink linkType="Reference" linkID="561148"&gt;561148&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event></TimeLine><Patents><Patent id="IN2538522"><Number>US-05866120</Number><Title>Method For Accelerating Clearance Of Hemorrhagic Blood From The Vitreous Humor With Hyaluronidase</Title></Patent></Patents><IsOptional>Y</IsOptional><CrossReferences><SourceEntity id="14690" type="Drug"><TargetEntity id="252783" type="siDrug">Hyaluronidase (ovine)</TargetEntity></SourceEntity><SourceEntity id="24620" type="Company"><TargetEntity id="4295901047" type="organizationId">Ista Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="14042" type="Company"><TargetEntity id="5000014741" type="organizationId">Allergan Inc</TargetEntity></SourceEntity><SourceEntity id="239" type="ciIndication"><TargetEntity id="10015916" type="MEDDRA"></TargetEntity><TargetEntity id="D005128" type="MeSH"></TargetEntity><TargetEntity id="-2056365523" type="omicsDisease"></TargetEntity><TargetEntity id="754" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2618" type="Action"><TargetEntity id="1601" type="Mechanism">Anti-CD44</TargetEntity><TargetEntity id="6926" type="Mechanism">CD44 Antigen Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="129807"><Title>Watson to license US rights to Columbia's progesterone products         </Title><CompanyPrincipal id="21742">Juniper Pharmaceuticals Inc</CompanyPrincipal><CompanyPartner id="21717">Actavis Inc</CompanyPartner><Type>Drug - Asset Divestment</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="62.0" min="62.0"></ValuePaid><ValueProjected accuracy="&gt;" max="261.0" min="170.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="0.3" min="0.3"></ValuePaid><ValueProjected accuracy="=" max="0.3" min="0.3"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="US">US</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>1499511</Reference><Type>Other</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.3" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1499511</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2009 Q4">10.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Contingent Equity</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1079340</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="45.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Contingent Equity</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1079340</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1079340</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="47.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="45.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Undisclosed</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="30.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1104547</Reference><Type>Loan/Credit</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="15.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2010 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Undisclosed</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="30.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="47.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2009 Q4">20.0</ReportedAmountMil></Value></Payment><Payment><Reference>1079340</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2009 Q4">20.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="438">Gynecological disorder</Indication><Indication id="1093">Amenorrhea</Indication><Indication id="374">Estrogen deficiency</Indication><Indication id="1080">Female infertility</Indication><Indication id="455">Premature labor</Indication></Indications><ActionsPrimary><Action id="624">Progesterone receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2659">Cardioprotectant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="1663">Gel formulation</Technology><Technology id="90">Steroid</Technology><Technology id="623">Vaginal formulation</Technology></Technologies><DateStart>2010-03-04T00:00:00Z</DateStart><DateEnd>2013-11-14T00:00:00Z</DateEnd><DateEventMostRecent>2013-11-14T00:00:00Z</DateEventMostRecent><Drugs><Drug id="12360"><DrugNameDisplay>progesterone (vaginal bioadhesive gel), Allergan/Merck Serono</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In March 2010, &lt;ulink linkType="Company" linkID="21717"&gt;Watson Pharmaceuticals&lt;/ulink&gt; (now Actavis) acquired exclusive US rights to &lt;ulink linkType="Company" linkID="21742"&gt;Columbia Laboratories&lt;/ulink&gt;' bioadhesive &lt;ulink linkType="Drug" linkID="12360"&gt;progesterone&lt;/ulink&gt; gel products (Crinone; Prochieve)  for infertility and secondary amenorrhea; Columbia would retain certain assets and rights to its progesterone business. The  transaction was subject to customary regulatory approval and was expected to close in Q2, 2010    [&lt;ulink linkType="Reference" linkID="1079340"&gt;1079340&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1079211"&gt;1079211&lt;/ulink&gt;].  In June 2010, Columbia received a subordinated term loan from Watson, to support development of Prochieve, the PREGNANT Study, and related development programs; at the time, approval of the complete deal was not expected until July 2010 [&lt;ulink linkType="Reference" linkID="1104547"&gt;1104547&lt;/ulink&gt;]. In July 2010, Watson completed acquisition of the US rights to the progesterone product line and  shares of Columbia common stock [&lt;ulink linkType="Reference" linkID="1113729"&gt;1113729&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1113461"&gt;1113461&lt;/ulink&gt;]. In February 2012, Columbia had transferred the new drug application for progesterone vaginal gel 8% to reduce the risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy to Watson [&lt;ulink linkType="Reference" linkID="1262252"&gt;1262252&lt;/ulink&gt;]. In November 2013, the companies agreed to terminate early their  supply agreement for Crinone; Actavis was granted US manufacturing rights [&lt;ulink linkType="Reference" linkID="1499511"&gt;1499511&lt;/ulink&gt;]. &lt;/para&gt;</Summary><TimeLine><Event><Date>2010-03-04T00:00:00Z</Date><Drugs><DrugLink id="12360" nameDisplay="progesterone (vaginal bioadhesive gel), Allergan/Merck Serono"></DrugLink></Drugs><Stage id="C3">Phase 3 Clinical</Stage><Summary>&lt;para&gt;In March 2010, &lt;ulink linkType="Company" linkID="21717"&gt;Watson Pharmaceuticals&lt;/ulink&gt; acquired exclusive US rights to &lt;ulink linkType="Company" linkID="21742"&gt;Columbia Laboratories&lt;/ulink&gt;' bioadhesive &lt;ulink linkType="Drug" linkID="12360"&gt;progesterone&lt;/ulink&gt; gel products (Crinone; Prochieve)  for infertility and secondary amenorrhea; Columbia would retain certain assets and rights to its progesterone business. Columbia would receive $47 million upfront,  up to $45.5 million in milestones and royalties of  10 - 20% of annual net sales for certain products. Milestones would be paid for successful completion of the PREGNANT study, regulatory filings and approvals, and product launches. Furthermore, Watson would acquire 11.2 million shares of Columbia common stock. The companies would collaborate on the phase III PREGNANT study for the prevention of preterm birth in women with a short cervix; anticipated clinical and regulatory costs for the indication would be covered by Columbia. Watson would cover excess costs and fund development of a second-generation vaginal progesterone product.  Watson would have the right to appoint a  member of Columbia's Board of Directors and  would immediately initiate US marketing activities.  Columbia is responsible for manufacturing the progesterone gel products; Asset sale complete per 7/6/2010 press release. The  transaction was subject to customary regulatory approval and was expected to close in Q2, 2010 [&lt;ulink linkType="Reference" linkID="1079340"&gt;1079340&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1079211"&gt;1079211&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2010-06-01T00:00:00Z</Date><Drugs><DrugLink id="12360" nameDisplay="progesterone (vaginal bioadhesive gel), Allergan/Merck Serono"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="1104547">1104547</Reference><Type>Loan/Credit</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2010 Q1" exchangeRateUS="1">15</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In June 2010, Columbia received a subordinated term loan from Watson of $15 million, to support development of Prochieve, the PREGNANT Study, and related development programs. The loan was payable upon maturity on December 31, 2011, with compounded monthly interest at a rate of 4% per year. Should Watson have closed its deal (expected in July 2010) to acquire progesterone-related assets from Columbia before the maturity date, accrued interest on the loan would be forgiven. If, however, Columbia were to finalize a similar deal with another party, or change the status of its control over these assets prior to August 31, 2011,  the loan plus interest would be due in their entirety, plus a pre-payment penalty of $2 million [&lt;ulink linkType="Reference" linkID="1104547"&gt;1104547&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2010-07-01T00:00:00Z</Date><Drugs><DrugLink id="12360" nameDisplay="progesterone (vaginal bioadhesive gel), Allergan/Merck Serono"></DrugLink></Drugs><Summary>&lt;para&gt;In July 2010, Columbia  stockholders approved the sale of substantially all of its progesterone related assets to Watson. A share increase necessary to complete the transaction was also approved. The transaction was  expected to close within three business days [&lt;ulink linkType="Reference" linkID="1112223"&gt;1112223&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1112124"&gt;1112124&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2010-07-02T00:00:00Z</Date><Drugs><DrugLink id="12360" nameDisplay="progesterone (vaginal bioadhesive gel), Allergan/Merck Serono"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="1113461">1113461</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2010 Q2" exchangeRateUS="1">47</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In July 2010, Watson completed acquisition of the US rights to the progesterone product line and 11.2 million shares of Columbia common stock. The upfront fee had now been paid. Columbia would be deft free. Watson forgave all principal and accrued interest on the $15 million subordinated term loan [&lt;ulink linkType="Reference" linkID="1113729"&gt;1113729&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1113461"&gt;1113461&lt;/ulink&gt;].  &lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2011-05-05T00:00:00Z</Date><Drugs><DrugLink id="12360" nameDisplay="progesterone (vaginal bioadhesive gel), Allergan/Merck Serono"></DrugLink></Drugs><Summary>&lt;para&gt;By May 2011,  Columbia would be eligible to receive either a $6 million or $8 million milestone payment based upon achievement of certain statistical results of the PREGNANT study. Columbia had provided written notice to Watson that the $6 million milestone was achieved. However, Watson provided written notice that the milestone had not been achieved. The parties expected to resolve the dispute pursuant to the terms of the agreement. No revenue had been recognized to date for this potential milestone payment [&lt;ulink linkType="Reference" linkID="1189014"&gt;1189014&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2012-02-13T00:00:00Z</Date><Drugs><DrugLink id="12360" nameDisplay="progesterone (vaginal bioadhesive gel), Allergan/Merck Serono"></DrugLink></Drugs><Summary>&lt;para&gt;In February 2012, Columbia had transferred the new drug application for progesterone vaginal gel 8% to reduce the risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy to Watson. Watson was continuing to work with FDA for the had the review of the NDA at that time. Watson had the full rights and responsible for all regulatory activities and sponsor obligations relating to NDA application as of February 10, 2012.  Columbia transferred the NDA for progesterone vaginal gel 8% to Watson, which has full rights and regulatory responsibility for all activities and sponsor obligations relating to this application as of 2/10/12. There are no incremental payments associated with the transfer, and Columbia maintains its financial interest in the product and its role in the companies’ Joint Development Committee. Watson received a complete response letter from the FDA for progesterone vaginal gel 8%, stating that the trial did not meet the level of statistical significance generally expected to support the approval of the product in the US market from a single trial. Financial terms were undisclosed [&lt;ulink linkType="Reference" linkID="1262252"&gt;1262252&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2013-01-24T00:00:00Z</Date><Drugs><DrugLink id="12360" nameDisplay="progesterone (vaginal bioadhesive gel), Allergan/Merck Serono"></DrugLink></Drugs><Summary>&lt;para&gt;In January 2013,  Watson changed its name to Actavis, following Watson's aquisition of Actavis [&lt;ulink linkType="Reference" linkID="1362759"&gt;1362759&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>M&amp;amp;A Activity</Type></Event><Event><Date>2013-11-14T00:00:00Z</Date><Drugs><DrugLink id="12360" nameDisplay="progesterone (vaginal bioadhesive gel), Allergan/Merck Serono"></DrugLink></Drugs><PaymentsToPartner><Payment><Reference id="1499511">1499511</Reference><Type>Other</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2013 Q3" exchangeRateUS="1">0.3</USDAmountMil></Value></Payment></PaymentsToPartner><Stage id="L">Launched</Stage><Summary>&lt;para&gt;- In November 2013, the companies agreed to terminate early their  supply agreement for Crinone, which was originally due to expire in May 2015 and had provided for Columbia to receive a 10% mark-up on its cost of goods of all product sold to Actavis. &lt;/para&gt;&lt;para&gt;- Actavis would manufacture Crinone in-house following the termination of the agreement. &lt;/para&gt;&lt;para&gt;- Actavis agreed to make a one-time payment of $300,000 for crinone US manufacturing rights and to offset estimated lost production margin through the original supply agreement. &lt;/para&gt;&lt;para&gt;- Actavis would purchase all remaining work-in-progress and finished Crinone in Columbia's inventory. &lt;/para&gt;&lt;para&gt;- Columbia would continue to receive at least a 10% royalty on Actavis' US net sales under the terms of the 2010 purchase and collaboration agreement.&lt;/para&gt;&lt;para&gt;- The parties agreed to terminate early their supply agreement for CRINONE, otherwise terminated in May 2015, provided for Columbia to receive a 10% mark-up on its cost of goods of all product sold to Actavis (previously Watson).&lt;/para&gt;&lt;para&gt;- Actavis would pay a one-time fee of $0.03M to offset estimated lost production margin through the original term of the supply agreement.&lt;/para&gt;&lt;para&gt;- Columbia repurchased 1.4M shares of its common stock, par value $0.01/shar, from Coventry Acquisition, subsidiary of Actavis at $6.08/share.&lt;/para&gt;&lt;para&gt;- The transaction will reduce the total issued and outstanding shares of common stock by 11.5% from 12.15M to 10.75M. [&lt;ulink linkType="Reference" linkID="1499511"&gt;1499511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;b&gt;Termination Reason : &lt;/b&gt; M&amp;amp;A – Contractual termination &lt;/para&gt;&lt;para&gt;&lt;b&gt;Post termination payments : &lt;/b&gt; 10% royalties &lt;/para&gt;&lt;para&gt;&lt;b&gt;Product Reversion Rights : &lt;/b&gt; to Licensee – with royalty &lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="21742" type="Company"><TargetEntity id="4295903741" type="organizationId">Juniper Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="21717" type="Company"><TargetEntity id="4295905312" type="organizationId">Allergan Finance LLC</TargetEntity></SourceEntity><SourceEntity id="1080" type="ciIndication"><TargetEntity id="N97" type="ICD10"></TargetEntity><TargetEntity id="628" type="ICD9"></TargetEntity><TargetEntity id="10021928" type="MEDDRA"></TargetEntity><TargetEntity id="D007247" type="MeSH"></TargetEntity><TargetEntity id="-932722270" type="omicsDisease"></TargetEntity><TargetEntity id="553" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1093" type="ciIndication"><TargetEntity id="10001928" type="MEDDRA"></TargetEntity><TargetEntity id="D000568" type="MeSH"></TargetEntity><TargetEntity id="-2029219374" type="omicsDisease"></TargetEntity><TargetEntity id="1236" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="374" type="ciIndication"><TargetEntity id="10030247" type="MEDDRA"></TargetEntity><TargetEntity id="3331" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="438" type="ciIndication"><TargetEntity id="538" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="455" type="ciIndication"><TargetEntity id="O60" type="ICD10"></TargetEntity><TargetEntity id="10036600" type="MEDDRA"></TargetEntity><TargetEntity id="D007752" type="MeSH"></TargetEntity><TargetEntity id="-699701292" type="omicsDisease"></TargetEntity><TargetEntity id="567" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="624" type="Action"><TargetEntity id="559" type="Mechanism">Progesterone Receptor Agonists</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="129831"><Title>Paul Capital to receive royalty stream from Menarini's commercialization of Vernalis' frovatriptan</Title><CompanyPrincipal id="15262">Vernalis plc</CompanyPrincipal><CompanyPartner id="1038484">Paul Capital Healthcare</CompanyPartner><Type>Drug - Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="~" max="27.558968" min="27.558968"></ValuePaid><ValueProjected accuracy="&gt;" max="58.4" min="58.4"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="&gt;" max="32.57" min="32.57"></ValuePaid><ValueProjected accuracy="&gt;" max="65.14" min="65.14"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="X5">Europe</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>1080457</Reference><Type>Undisclosed</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="32.57" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1080457</Reference><Type>Other Equity</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1080457</Reference><Type>Other Equity</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>898383</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1080457</Reference><Type>Undisclosed</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="32.57" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>898383</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>898383</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="29.2" usdExchangeRate="1.0" usdExchangeRatePeriod="2008 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>898383</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="29.2" usdExchangeRate="1.0" usdExchangeRatePeriod="2008 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>898383</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>898383</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="210">Migraine</Indication></Indications><ActionsPrimary><Action id="10">5-HT 1d receptor agonist</Action><Action id="8">5-HT 1b receptor agonist</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><DateStart>2008-04-21T00:00:00Z</DateStart><DateEnd>2010-02-11T00:00:00Z</DateEnd><DateEventMostRecent>2010-02-11T00:00:00Z</DateEventMostRecent><Drugs><Drug id="9022"><DrugNameDisplay>frovatriptan</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In April 2008, &lt;ulink linkType="Company" linkID="15262"&gt;Vernalis&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="1038484"&gt;Paul Capital Healthcare&lt;/ulink&gt; entered into an agreement relating to &lt;ulink linkType="Drug" linkID="9022"&gt;frovatriptan&lt;/ulink&gt;, whereby Paul Capital would receive 90% of Vernalis' royalty stream from its European commercialization partner for the drug, &lt;ulink linkType="Company" linkID="18053"&gt;The Menarini Group&lt;/ulink&gt;    [&lt;ulink linkType="Reference" linkID="898383"&gt;898383&lt;/ulink&gt;].  In February 2010,    Menarini was  terminating the agreement with Paul, regaining 100% of its royalty rights from Menarini (25.25% of net sales) [&lt;ulink linkType="Reference" linkID="1080457"&gt;1080457&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2008-04-21T00:00:00Z</Date><Drugs><DrugLink id="9022" nameDisplay="frovatriptan"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="898383">898383</Reference><Type>Undisclosed</Type><Value><Accuracy sortorder="5">~</Accuracy><ReportedAmountMil currency="EUR">18.4</ReportedAmountMil><USDAmountMil exchangeRatePeriod="2008 Q1" exchangeRateUS="1.49777">27.558968</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="R">Registered</Stage><StageNotes>&lt;para&gt;Product is approved for migraine in the U.S., Canada, and Europe&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;In April 2008, &lt;ulink linkType="Company" linkID="15262"&gt;Vernalis&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="1038484"&gt;Paul Capital Healthcare&lt;/ulink&gt; entered into an agreement relating to &lt;ulink linkType="Drug" linkID="9022"&gt;frovatriptan&lt;/ulink&gt;, whereby Paul Capital would receive 90% of Vernalis' royalty stream from its European commercialization partner for the drug, &lt;ulink linkType="Company" linkID="18053"&gt;The Menarini Group&lt;/ulink&gt;, in return for approximately EUR 18.4 million (approximately $27.6 million).  Frovatriptan is a 5-HT receptor agonist that prevents dilation of arteries supplying blood to the head. Vernalis would continue to supply the active compound to Menarini. It was  approved for acute treatment of migraine in Europe, the United States, Canada and seven Central American countries. Vernalis licensed the European rights to Menarini in 1999, for an 8-10% royalty plus a 20% transfer price on the supply of product (see separate transaction) Vernalis retained 10% of its royalty stream to cover the cost of API supplied to Menarini by Vernalis     [&lt;ulink linkType="Reference" linkID="898383"&gt;898383&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2010-02-11T00:00:00Z</Date><Drugs><DrugLink id="9022" nameDisplay="frovatriptan"></DrugLink></Drugs><PaymentsToPartner><Payment><Reference id="1080457">1080457</Reference><Type>Undisclosed</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2009 Q4" exchangeRateUS="1">32.57</USDAmountMil></Value></Payment><Payment><Reference id="1080457">1080457</Reference><Type>Other Equity</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPartner><Stage id="R">Registered</Stage><StageNotes>&lt;para&gt;frovatriptan was registered&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;However, In February 2010,   In connection with a 30M pound financing, Menarini was  terminating the agreement with Paul, regaining 100% of its royalty rights from Menarini (25.25% of net sales), through a $32.57M cash payment to Paul (12% more than the amount of the principal "loan", over approximately two years).&lt;/para&gt;&lt;para&gt;- Paul Capital would  also subscribe for 2.1 million Vernalis warrants.&lt;/para&gt;&lt;para&gt;- Menarini sales of frovatriptan were EUR 32.4 million  in 2009 [&lt;ulink linkType="Reference" linkID="1646155"&gt;1646155&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1080457"&gt;1080457&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;b&gt;Termination Reason : &lt;/b&gt; Other Vernalis raised enough money to cover its expenses, and paid off Paul Capital for the "loan" &lt;/para&gt;&lt;para&gt;&lt;b&gt;Product Reversion   Rights : &lt;/b&gt; to Licensor – royalty free &lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="9022" type="Drug"><TargetEntity id="212285" type="siDrug">Frovatriptan</TargetEntity></SourceEntity><SourceEntity id="1038484" type="Company"><TargetEntity id="5035525365" type="organizationId">Paul Capital Healthcare</TargetEntity></SourceEntity><SourceEntity id="15262" type="Company"><TargetEntity id="4295894372" type="organizationId">Vernalis Ltd</TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"></TargetEntity><TargetEntity id="10027599" type="MEDDRA"></TargetEntity><TargetEntity id="D008881" type="MeSH"></TargetEntity><TargetEntity id="-672899670" type="omicsDisease"></TargetEntity><TargetEntity id="27" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="10" type="Action"><TargetEntity id="222" type="Mechanism">5-HT1D Agonists</TargetEntity></SourceEntity><SourceEntity id="8" type="Action"><TargetEntity id="221" type="Mechanism">5-HT1B Agonists</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="145175"><Title>SciClone to distribute Zensun's Neucardin in China, Hong Kong and Macau      </Title><CompanyPrincipal id="1003929">Zensun (Shanghai) Sci-Tech Co Ltd</CompanyPrincipal><CompanyPartner id="19829">SciClone Pharmaceuticals Inc</CompanyPartner><Type>Drug - Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="5.0" min="0.0"></ValuePaid><ValueProjected accuracy="&gt;" max="86.0" min="44.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="3.5" min="3.5"></ValuePaid><ValueProjected accuracy="=" max="15.5" min="15.5"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="CN">China</Territory><Territory id="HK">Hong Kong</Territory><Territory id="MO">Macau</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>2109437</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2018 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2109437</Reference><Type>Loan/Credit</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="12.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2018 Q1">0.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1422953</Reference><Type>Other</Type><Value accuracy="&gt;="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="10.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1422953</Reference><Type>Loan/Credit</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="12.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1498885</Reference><Type>Upfront Payment</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="5.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1422953</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="18.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Sales Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1422953</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="18.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Sales Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1422953</Reference><Type>Loan/Credit</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="12.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1422953</Reference><Type>Other</Type><Value accuracy="&gt;="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="10.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q1">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="55">Cardiac failure</Indication></Indications><ActionsPrimary><Action id="8685">Erbb4 tyrosine kinase receptor stimulator</Action><Action id="12667">Neuregulin-1 ligand</Action><Action id="8683">Erbb2 tyrosine kinase receptor stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="966">Cardiac agent</Action></ActionsSecondary><Technologies><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><DateStart>2013-05-13T00:00:00Z</DateStart><DateEnd>2018-06-22T00:00:00Z</DateEnd><DateEventMostRecent>2018-06-22T00:00:00Z</DateEventMostRecent><Drugs><Drug id="59496"><DrugNameDisplay>Neucardin</DrugNameDisplay><PhaseHighestStart id="C3">Phase 3 Clinical</PhaseHighestStart><PhaseHighestNow id="PR">Pre-registration</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In May 2013, &lt;ulink linkType="Company" linkID="19829"&gt;SciClone Pharmaceuticals&lt;/ulink&gt; signed a license agreement to acquire an exclusive rights to promote, market, distribute and sell &lt;ulink linkType="Company" linkID="1003929"&gt;Zensun (Shanghai) Science &amp;amp; Technology&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="59496"&gt;Neucardin&lt;/ulink&gt; in China, Hong Kong and Macau [&lt;ulink linkType="Reference" linkID="1422953"&gt;1422953&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1641605"&gt;1641605&lt;/ulink&gt;]. By September 2013, upfront payments for the nine months ended September 30 were reported by SciClone   [&lt;ulink linkType="Reference" linkID="1498885"&gt;1498885&lt;/ulink&gt;]. In June 2018,   Zensun (Shanghai) Sci-Tech regained the  sales interest for Neucardin in China from SciClone Pharmaceuticals [&lt;ulink linkType="Reference" linkID="2109437"&gt;2109437&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2018-06-22T00:00:00Z</Date><Drugs><DrugLink id="59496" nameDisplay="Neucardin"></DrugLink></Drugs><PaymentsToPartner><Payment><Reference id="2109437">2109437</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2018 Q1" exchangeRateUS="1">3.5</USDAmountMil></Value></Payment></PaymentsToPartner><Stage id="C3">Phase 3 Clinical</Stage><StageNotes>&lt;para&gt;Neucardin in phase III cardiac failure&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In June 2018,   Zensun (Shanghai) Sci-Tech regained the  sales interest for Neucardin in China from SciClone Pharmaceuticals.&lt;/para&gt;&lt;para&gt;- Zensun would pay back a total of RMB 100 million including  $ 3.5 million initial payment and $ 12 million loan and related interest  [&lt;ulink linkType="Reference" linkID="2109437"&gt;2109437&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event><Event><Date>2013-05-13T00:00:00Z</Date><Drugs><DrugLink id="59496" nameDisplay="Neucardin"></DrugLink></Drugs><Stage id="C3">Phase 3 Clinical</Stage><StageNotes>&lt;para&gt;Zensun has already filed an NDA in China to obtain accelerated market approval of Neucardin (Source: Zensun's website)&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In May 2013, &lt;ulink linkType="Company" linkID="19829"&gt;SciClone Pharmaceuticals&lt;/ulink&gt; signed a license agreement to acquire an exclusive rights to promote, market, distribute and sell &lt;ulink linkType="Company" linkID="1003929"&gt;Zensun (Shanghai) Science &amp;amp; Technology&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="59496"&gt;Neucardin&lt;/ulink&gt; in China, Hong Kong and Macau.&lt;/para&gt;&lt;para&gt;- Neucardin is a genetically engineered recombinant peptide fragment of neuregulin-1 (?2a isoform) in development for chronic heart failure.&lt;/para&gt;&lt;para&gt;- Zensun would be responsible for the manufacturing and supply of the drug and SciClone would  be responsible for all aspects of commercialization, including the pre- and post-launch activities for the drug.&lt;/para&gt;&lt;para&gt;- Zensun would receive milestone payments of up to $18.5 million and would eligible for additional payments of $10 million upon the approval of Neucardin by subcutaneous infusion.&lt;/para&gt;&lt;para&gt;- Further indications and improved product forms of the drug would result in additional payments.&lt;/para&gt;&lt;para&gt;- SciClone would also provide  a secured loan of $12 million  that Zensun would use in future. The companies  agreed to negotiate a supplemental license and supply agreement [&lt;ulink linkType="Reference" linkID="1422953"&gt;1422953&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1641605"&gt;1641605&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2013-09-30T00:00:00Z</Date><Drugs><DrugLink id="59496" nameDisplay="Neucardin"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="1498885">1498885</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="4">=&lt;</Accuracy><USDAmountMil exchangeRatePeriod="2013 Q2" exchangeRateUS="1">5</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;By September 2013, upfront payments of $5 million for the nine months ended September 30 were reported by SciClone. This amount was related to the license agreements signed with Zensun and &lt;ulink linkType="Company" linkID="1023258"&gt;Taiwan Liposome&lt;/ulink&gt;. Further financial terms were not disclosed [&lt;ulink linkType="Reference" linkID="1498885"&gt;1498885&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="59496" type="Drug"><TargetEntity id="455534" type="siDrug">Neuregulin-1</TargetEntity></SourceEntity><SourceEntity id="19829" type="Company"><TargetEntity id="4295907889" type="organizationId">SciClone Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1003929" type="Company"><TargetEntity id="5035555114" type="organizationId">Zensun Shanghai Sci &amp; Tech Co Ltd</TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"></TargetEntity><TargetEntity id="10007554" type="MEDDRA"></TargetEntity><TargetEntity id="D006333" type="MeSH"></TargetEntity><TargetEntity id="-1323949873" type="omicsDisease"></TargetEntity><TargetEntity id="237" type="siCondition"></TargetEntity></SourceEntity></CrossReferences></Deal></ns2:com.thomsonreuters.ls.service.contract.soap.deals.v2.DealRecordsOutput>